IndietroBlood: Hemostasis, Clotting, and Transfusion – Anatomy & Physiology I Study Notes
Guida di studio - Note intelligenti
Appunti personalizzati basati sui tuoi materiali, ampliati con definizioni chiave, esempi e contesto.
Blood: Hemostasis, Clotting, and Transfusion
Overview
This section covers the physiology of blood, focusing on hemostasis, coagulation, clot retraction and fibrinolysis, disorders of hemostasis, and blood transfusion. Understanding these processes is essential for grasping the mechanisms that maintain vascular integrity and the clinical implications of blood group compatibility.
Hemostasis
Coagulation
Hemostasis is the process that stops bleeding after vascular injury. Coagulation is a critical phase where blood is transformed from liquid to gel, reinforcing the platelet plug with fibrin threads to seal vessel breaks.
Clotting factors (procoagulants): Mostly plasma proteins, numbered I to XIII in order of discovery. Vitamin K is required to synthesize four of these factors.
Phases of coagulation:
Phase 1: Formation of prothrombin activator via intrinsic and extrinsic pathways.
Phase 2: Prothrombin activator converts prothrombin to thrombin.
Phase 3: Thrombin converts fibrinogen to fibrin, forming a mesh that traps blood cells.
Intrinsic pathway: Initiated by damage inside the vessel or in vitro (e.g., test tube). Triggered by negatively charged surfaces (collagen, activated platelets).
Extrinsic pathway: Initiated by external trauma, releasing tissue factor (TF/Factor III). Faster than intrinsic pathway.
Factor X: Activated in both pathways, then complexes with Ca2+, PF3 (platelet factor 3), and Factor V to form prothrombin activator.
Key equation:
Additional info: Vitamin K deficiency impairs synthesis of several clotting factors, increasing bleeding risk.
Blood Clotting Factors (Procoagulants)
Clotting factors are essential plasma proteins and cofactors involved in the coagulation cascade. Their deficiency or dysfunction leads to bleeding disorders.
Factor Number | Factor Name | Source | Main Function |
|---|---|---|---|
I | Fibrinogen | Plasma protein | Forms fibrin threads of clot |
II | Prothrombin | Plasma protein | Converted to thrombin |
III | Tissue factor (TF) | Plasma membrane glycoprotein | Activates extrinsic pathway |
IV | Calcium ions (Ca2+) | Plasma | Essential for all stages of coagulation |
V | Proaccelerin | Plasma protein | Common pathway cofactor |
VIII | Antihemophilic factor | Plasma protein | Deficiency causes hemophilia A |
IX | Plasma thromboplastin component | Plasma protein | Deficiency causes hemophilia B |
XIII | Fibrin stabilizing factor | Plasma protein | Cross-links fibrin, stabilizes clot |
Additional info: | Other factors (VI, VII, X, XI, XII) also play roles in the cascade. |
Clot Retraction & Fibrinolysis
After a clot forms, it must be stabilized and eventually removed as healing occurs.
Clot retraction: Actin and myosin in platelets contract, pulling on fibrin strands and squeezing serum from the clot. This draws ruptured vessel edges together.
Serum: Plasma minus clotting proteins.
Platelet-derived growth factor (PDGF): Released by platelets, stimulates division of smooth muscle cells and fibroblasts to rebuild vessel wall.
Vascular endothelial growth factor (VEGF): Stimulates endothelial cells to multiply and restore lining.
Fibrinolysis
Fibrinolysis: Process of clot removal when no longer needed.
Plasmin: Key enzyme that digests fibrin; precursor is plasminogen, incorporated into the clot.
tPA (tissue plasminogen activator): Released by endothelial cells, activates plasminogen.
Begins within 2 days and continues until clot is dissolved.
Key equation:
Factors Limiting Clot Growth or Formation
Mechanisms Limiting Clot Size
Normal physiology prevents excessive clotting by removing or inhibiting activated clotting factors.
Swift removal and dilution of clotting factors by flowing blood.
Inhibition of activated clotting factors by plasma proteins (e.g., antithrombin III, protein C).
Heparin (from basophils and mast cells) enhances antithrombin III activity.
Smooth endothelial lining and endothelial-derived NO & prostacyclin prevent undesirable clotting.
Disorders of Hemostasis
Thromboembolic Disorders
These disorders involve undesirable clot formation within blood vessels.
Thrombus: Clot that develops and persists in an unbroken vessel, potentially blocking circulation and causing tissue death.
Embolus: Thrombus that breaks free and floats in the bloodstream.
Embolism: Embolus obstructs a vessel (e.g., pulmonary or cerebral embolism).
Risk factors: Atherosclerosis, inflammation, slow blood flow, immobility.
Treatment: Drugs such as tPA, streptokinase to dissolve clots via plasmin.
Bleeding Disorders
Thrombocytopenia: Deficient number of circulating platelets due to bone marrow suppression or destruction. Platelet count <50,000/μl is diagnostic. Treatment is transfusion of concentrated platelets (temporary relief).
Impaired liver function: Inability to synthesize procoagulants (clotting factors). Causes include vitamin K deficiency, hepatitis, cirrhosis. Liver disease can also prevent bile production, impairing vitamin K absorption.
Hemophilia: Hereditary bleeding disorders. Hemophilia A (factor VIII deficiency, most common), Hemophilia B (factor IX deficiency).
Blood Transfusion
Principles and Practice
Blood transfusion is used to replace lost blood volume and restore oxygen-carrying capacity.
Cardiovascular system compensates for blood loss by reducing vessel volume and increasing RBC production.
Volume must be replaced immediately with normal saline or multiple-electrolyte solution (Ringer's solution).
Whole blood transfusion for substantial loss or thrombocytopenia; packed red cells (PRBC) for anemia.
Donor blood is mixed with heparin (anticoagulant).
Blood groups must be determined to prevent fatal transfusion reactions.
Human Blood Groups
ABO Blood Groups
Blood groups are classified based on the presence or absence of antigens (agglutinogens) on RBC membranes.
Antigens: Substances on RBCs that can trigger immune responses.
Agglutinogens: RBC antigens that promote agglutination.
Agglutinins: Antibodies in plasma that act against transfused RBCs with foreign antigens.
ABO system: Based on presence/absence of A and B antigens.
RBC Type | Antigens on RBCs | Antibodies in Plasma | Can Receive Blood From |
|---|---|---|---|
A | A | Anti-B | A, O |
B | B | Anti-A | B, O |
AB | A and B | None | A, B, AB, O (universal recipient) |
O | None | Anti-A, Anti-B | O (universal donor) |
Additional info: Type O is the universal donor because it lacks A and B antigens; type AB is the universal recipient because it lacks anti-A and anti-B antibodies.
Rh Blood Groups
52 named Rh agglutinogens; C, D, and E are most common.
Rh+ indicates presence of D antigen; 85% of North Americans are Rh+.
Anti-Rh antibodies are not spontaneously formed in Rh- individuals but can form after exposure to Rh+ blood.
Second exposure to Rh+ blood results in typical transfusion reaction.
Rh- mothers carrying Rh+ babies are treated with RhoGAM to prevent erythroblastosis fetalis (hemolytic disease of the newborn).
Transfusion Reactions
Mechanism and Consequences
Transfusion reactions occur if mismatched blood is infused, primarily due to recipient's antibodies (agglutinins) attacking donor RBCs.
Agglutination and clogging of small vessels.
RBCs rupture, releasing hemoglobin into bloodstream.
Blocked flow to tissues, reduced oxygen-carrying ability, and possible kidney failure due to hemoglobin precipitation in renal tubules.
Symptoms: fever, chills, nausea, vomiting, general toxicity.
Prevention: administer alkaline fluids and diuretics to dilute and remove hemoglobin.
Autologous transfusion: patient donates own blood prior to surgery.
Blood Typing
Principles and Cross-Matching
Donor blood is mixed with antibodies against common agglutinogens; clumping indicates presence of antigen.
Blood is typed for ABO and Rh factor.
Cross-matching: Typing between specific donor and recipient. Mix recipient's serum with donor RBCs and vice versa.
Review Questions
Fibrinolysis is increased by: Activation of plasminogen, release of tPA, and heparin.
Transfusion reaction concerns: Clogging of small vessels, lysis of donated RBCs, blockage of kidney tubules; donor antibodies attacking recipient RBCs is not a major concern.